Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine + Rituximab QT Interval Study in NHL/MCL
NCT01073163Phase 3Completed
- Sponsor
- Cephalon, Inc.
- Start
- Feb 2010
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of bendamustine in Indolent Non-Hodgkin Lymphoma (INHL), mantle cell lymphoma (MCL), sponsored by Cephalon, Inc.. Started Feb 2010; status: completed.
02
Drugs
bendamustine
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01073163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01073163.